Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics is a promising company in the regenerative medicine and cell therapy space, with a singular focus on developing fibroblast-based therapies for a variety of chronic diseases. Their deep IP moat, platform versatility across indications, and scalable manufacturing potential set them apart from other companies in the sector and are key drivers of long-term value. Upcoming catalysts to monitor include post-split trading behavior, maintenance of NASDAQ compliance, and progress across their fibroblast-based programs.

Bears say

FibroBiologics is facing uncertainty about its future potential due to the near-term questions surrounding its Phase 1/2 trial for CYWC628 in diabetic foot ulcers, with interim data expected in 1H26. Although the company's proprietary fibroblast spheroid technology shows promise in wound healing indications, its expansion into burn injuries presents a new set of challenges, including clinical/regulatory, partnership/financial, and market share risks. Additionally, the burn care market, while significant, is highly competitive, and FibroBiologics will need to demonstrate the superiority of its approach in order to gain market share.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.